Home › Funds › Schonfeld Strategic Advisors LLC › INBX
Schonfeld Strategic Advisors LLC position in INBX
INHIBRX BIOSCIENCES INC · Health Care
Schonfeld Strategic Advisors LLC reported holding 827,280 shares of INBX (INHIBRX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$82.8M, representing 0.49% of its reported portfolio and ranking #18 among its reported holdings. Schonfeld Strategic Advisors LLC has disclosed INBX holdings in 11 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Schonfeld Strategic Advisors LLC's INBX position evolved
Schonfeld Strategic Advisors LLC first disclosed a stake in INBX in Q4 2023 at 89,330 shares (US$3.4M). The position peaked in Q3 2026 at 827,280 shares, worth US$82.8M. Across 11 filings, Schonfeld Strategic Advisors LLC increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 827,280 shares valued at US$82.8M — an increase of 129,694 shares quarter over quarter.. Notable position changes include a 90% increase in Q3 2024 (shares fell 2% over the following quarter), a 120% increase in Q4 2025 (shares fell 15% over the following quarter), a 174% increase in Q2 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 89.33K | $3.39M | New |
| Q2 2024 | 75.98K | $1.08M | New |
| Q3 2024 | 144.18K | $2.26M | Add |
| Q4 2024 | 144.18K | $2.22M | Hold |
| Q1 2025 | 144.18K | $2.02M | Hold |
| Q2 2025 | 154.79K | $2.21M | Add |
| Q3 2025 | 97.38K | $3.28M | Reduce |
| Q4 2025 | 214.72K | $16.96M | Add |
| Q1 2026 | 254.83K | $17.13M | Add |
| Q2 2026 | 697.59K | $66.10M | Add |
| Q3 2026 | 827.28K | $82.79M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INBX and 13F data
INBX (INHIBRX BIOSCIENCES INC) is a Health Care company. 40 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$129.3M), Sanofi (US$115.9M), Sofinnova Investments, Inc. (US$39.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INBX
- PERCEPTIVE ADVISORS LLC 1.29M sh · $129.35M · Q3 2026
- Sanofi 1.16M sh · $115.89M · Q3 2026
- Sofinnova Investments, Inc. 391.62K sh · $39.19M · Q3 2026
- Parkman Healthcare Partners LLC 360.26K sh · $36.05M · Q3 2026
- PFM Health Sciences, LP 320.33K sh · $32.06M · Q3 2026
- Soleus Capital Management, L.P. 210.00K sh · $21.02M · Q3 2026
- First Turn Management, LLC 171.51K sh · $17.16M · Q3 2026
- Trails Edge Capital Partners, LP 170.00K sh · $17.01M · Q3 2026
- Cormorant Asset Management, LP 50.00K sh · $5.00M · Q3 2026
More on Schonfeld Strategic Advisors LLC
FAQ
How long has Schonfeld Strategic Advisors LLC held INBX?
Schonfeld Strategic Advisors LLC has disclosed INBX holdings in 11 of the last 12 reported quarters, going back to Q4 2023.
What is Schonfeld Strategic Advisors LLC's current position in INBX?
As of Q3 2026, Schonfeld Strategic Advisors LLC holds 827.28K shares of INBX (INHIBRX BIOSCIENCES INC), valued at $82.79M, representing 0.49% of its reported portfolio and ranking #18.
Has Schonfeld Strategic Advisors LLC been buying or selling INBX?
In the latest 13F filing (Q3 2026), Schonfeld Strategic Advisors LLC increased its position in INBX. The position peaked in Q3 2026 at 827.28K shares.
Which other funds hold INBX?
Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Sanofi, Sofinnova Investments, Inc., among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.